Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
The Uromigos
The Uromigos
The EST Hangout
Edmonton Sports Talk
Point Taken with Steve Scaffidi & Kristin Brey
620 WTMJ
CBN Tecnologia - Techtudo
CBN
Rambam Yomi
Rabbi Dov Winston
Chasing the Yield
Kevin Bae
Takeoff with John Clark: Philly Sports Interviews
NBC Sports Philadelphia
Bozeman News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The Ringer Gambling Show
The Ringer
FBCWF
First Baptist Church of Wichita Falls, TX
Le 26.30
France Inter
DLLS Dallas Cowboys Podcast
DLLS Sports, ALLCITY Network
Vermont Viewpoint
Vermont Viewpoint
The Vince Everett Ellison Show
Media Squatch
Hoops Tonight with Jason Timpf
iHeartPodcasts and The Volume
Oakland News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Reno News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Explaining the Faith with Fr. Chris Alar
The Marian Fathers
No Son Horas
Chumel Torres
GiMBoX
Delta Radio
Baton Rouge News Today | 2 Min News | The Daily News Now!
The Daily News Now!
RTL soir
RTL
Hey Unpopular
Hey Unpopular
The Revival Motoring Podcast
Revival Motoring
En casa de Herrero
esRadio
Next on the Tee: Where Golf Legends Live & Your Game Gets Better
Chris Mascaro - Golf Podcast Host
La Caminera con Tania Rincón, Fer Gay y Fran Hevia
MVS Radio
Política
CBN
Vera Magalhães - Viva Voz
CBN
The State of It
The Times
Linchpin Conversations
Pat Sherwood
Detroit Tigers News Today | 2 Min News | The Daily News Now!
The Daily News Now!
Vlad Savchuk Podcast
Vladimir Savchuk
The Kevin O'Connor Show
Yahoo Sports
This Is Nashville
WPLN News - Nashville Public Radio
Tout
The Uromigos
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and ...
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent stud...
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and inn...
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts di...
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, c...
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of d...
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer a...
This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radi...
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-dri...
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-ri...
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment d...
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.